Sugi Predict

Sugi Predict / Compounds / SCHEMBL83993

SCHEMBL83993

SCHEMBL83993

CC(C)c1ccnc(N)n1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.56
▸ HRH4 Q9H3N8 6/20 0.41
▸ AURKA O14965 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ PRKACA P17612 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ HRH3 Q9Y5N1 3/20 0.40
▸ NUDT1 P36639 2/20 0.40
▸ CDK4 P11802 1/20 0.38
▸ CCNE1 P24864 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ TLR8 Q9NR97 1/20 0.38
▸ CHRNA7 P36544 1/20 0.38
▸ NOS3 P29474 1/20 0.38
▸ NOS1 P29475 1/20 0.38
▸ NOS2 P35228 1/20 0.38
▸ GRM4 Q14833 1/20 0.37
▸ BCL6 P41182 1/20 0.37
▸ ROCK1 Q13464 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29718738 1.00 POLB (0.56) POLBHRH4AURKAHSP90AA1PRKACA
SCHEMBL2033996 0.84 POLB (0.54) POLBHRH4AURKAHSP90AA1PRKACA
SCHEMBL2032932 0.83 POLB (0.53) POLBHRH4AURKAHSP90AA1PRKACA
SCHEMBL2039822 0.83 POLB (0.53) POLBHRH4AURKAHSP90AA1PRKACA
SCHEMBL2033811 0.83 POLB (0.53) POLBHRH4AURKAHSP90AA1PRKACA
SCHEMBL21556891 0.81 POLB (0.51) POLBHRH4AURKAHSP90AA1PRKACA
SCHEMBL12277549 0.79 POLB (0.63) POLBHRH4AURKAHSP90AA1PRKACA
SCHEMBL29776554 0.78 POLB (0.49) POLBHRH4AURKAHSP90AA1PRKACA
SCHEMBL16964290 0.77 POLB (0.47) POLBHRH4AURKAHSP90AA1PRKACA
SCHEMBL1474579 0.77 POLB (0.51) POLBHRH4AURKAHSP90AA1PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551813-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-07-11 — — EP claimed
EP-1551813-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-13 — — EP claimed
WO-2004032882-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-22 — — WO claimed
WO-2024227104-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 — — US disclosed
WO-2024073587-A1 N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 — — US disclosed
WO-2023183601-A1 METHODS OF SYNTHESIZING EGFR INHIBITORS SCORPION THERAPEUTICS, INC. (US) 2023-09-28 — — WO disclosed
CN-116640117-A Triazole LPAR1 antagonists and uses thereof 武汉人福创新药物研发中心有限公司 2023-08-25 — — CN disclosed
US-20070244138-A1 Mercaptoimidazoles as Ccr2 Receptor Antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-18 — — US disclosed
EP-1551813-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-07-11 — — EP disclosed
US-7241801-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-07-10 — — US disclosed
US-7241801-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-07-10 — — US disclosed
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant SCHERING CORPORATION 2007-06-21 — — US disclosed
US-7220735-B2 Benzimidazolone histamine H3 antagonists SCHERING CORPORATION (US) 2007-05-22 — — US disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 — — WO disclosed
EP-1551813-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-13 — — EP disclosed
WO-2004032882-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant CNR2, GPR119, GLP1R POLB 4772/4885HRH4 5/4885AURKA 3560/4885
US-20070244138-A1 Mercaptoimidazoles as Ccr2 Receptor Antagonists CCR2, CCR1, CCR5 POLB 2080/4885HRH4 124/4885AURKA 2086/4885
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF POLB 1279/4885HRH4 3833/4885AURKA 436/4885
US-20240226114-A1 INHIBITORS AND USES THEREOF KEAP1, NQO1, NFE2L2 POLB 3287/4885HRH4 3134/4885AURKA 3007/4885
US-20240025918-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS POLB 1744/4885HRH4 3929/4885AURKA 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.